Table 1 –
Baseline patient characteristics across all institutions
| Variable | CDK12 | HRD | TP53 | Other | p value a | |||
|---|---|---|---|---|---|---|---|---|
| Mutation frequency, n (%) | 46/317 (15) | 60/317 (19) | 109/317 (34) | 102/317 (32) | ||||
| Age at diagnosis (yr), median (IQR) | 65 (58, 74) | 60 (57, 68) | 62 (57, 70) | 64 (57, 73) | 0.046 | |||
| Ethnicity, n (%) | ||||||||
| Caucasian | 34/39 (87) | 40/51 (78) | 60/66 (91) | 32/37 (87) | 0.3 | |||
| Non-Caucasian | 5/39 | 11/51 | 6/66 | 5/37 | ||||
| Missing | 7/46 (15) | 9/60 (15) | 43/109 (39) | 65/102 (64) | ||||
| PSA at diagnosis (ng/ml), median (IQR) | 20.9 (12.0, 138.0) | 18.0 (6.9, 75.0) | 11.3 (6.3, 32.7) | 13.0 (7.4, 57.2) | 0.064 | |||
| Time to continuous androgen deprivation therapy initiation (mo), median (IQR) | 1.8 (0.1, 13.6) | 3.3 (0.5, 36.5) | 1.8 (1.0, 50.6) | 4.0 (2.0, 51.1) | 0.06 | |||
| Gleason score, n (%) | ||||||||
| ≥8 | 36/41 (88) | 38/52 (73) | 74/103 (72) | 56/94 (60) | 0.009 | |||
| <8 | 5/41 | 14/52 | 29/103 | 38/94 | ||||
| Missing | 5/46 (11) | 8/60 (13) | 6/109 (5.5) | 8/102 (7.8) | ||||
| Stage at diagnosis, n (%) | ||||||||
| 0 (localized) | 24/43 | 38/60 | 62/104 | 64/99 | 0.7 | |||
| 1 (metastatic) |
19/43 (44) | 22/60 (37) | 42/104 (40) | 35/99 (35) | ||||
| Missing | 3/46 (6.5) | 0/60 (0) | 5/109 (4.6) | 3/102 (2.9) | ||||
| Lymph node metastasis, n (%) | ||||||||
| 0 (no) | 11/41 | 23/52 | 26/69 | 14/39 | 0.4 | |||
| 1 (yes) | 30/41 (73) | 29/52 (56) | 43/69 (62) | 25/39 (64) | ||||
| Missing | 5/46 (11) | 8/60 (13) | 40/109 (37) | 63/102 (62) | ||||
| Bone metastasis, n (%) | ||||||||
| 0 (no) | 9/39 | 17/55 | 24/106 | 23/99 | 0.7 | |||
| 1 (yes) | 30/39 (77) | 38/55 (70) | 82/106 (77) | 76/99 (77) | ||||
| Missing | 7/46 (15) | 5/60 (8.3) | 3/109 (2.8) | 3/102 (2.9) | ||||
| Visceral metastasis, n (%) | ||||||||
| 0 (no) | 30/39 | 41/54 | 79/106 | 83/97 | 0.3 | |||
| 1 (yes) | 9/39 (23) | 13/54 (24) | 27/106 (26) | 14/97 (14) | ||||
| Missing | 7/46 (15) | 6/60 (10) | 3/109 (2.8) | 5/102 (4.9) | ||||
CDK12 = cyclin-dependent kinase 12; HRD = homologous recombination deficiency; IQR = interquartile range; PSA = prostate-specific antigen.
a
p values based on the Cox proportional hazard model.